Antiviral Activity of Ingavirin® in Experimental Lethal Influenza Due to Influenza Virus B in Albino Mice
Abstract
The protective activity of Ingavirin® against experimental infection caused by influenza B virus was studied on albino mice vs. Arbidol®. Oral use of Ingavirin® was shown to decrease the infectious titers of the virus in the animal lung tissue, to normalize the body weight dynamics, to lower the mortality and to increase the average lifespan vs. the placebo-treated animals. The activity of Ingavirin® was higher than that of the reference drug. The results allowed to consider Ingavirin® as a prospective agent for the treatment of influenza infection in humans.
About the Authors
V. V. Zarubaev
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences, St. Petersburg
Russian Federation
Russian Federation
A. V. Garshinina
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences, St. Petersburg
Russian Federation
Russian Federation
N. A. Kalinina
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences, St. Petersburg
Russian Federation
Russian Federation
A. A. Shtro
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences, St. Petersburg
Russian Federation
Russian Federation
V. E. Nebolsin
JSC Valenta Pharm Co., Moscow
Russian Federation
Russian Federation
O. I. Kiselev
Research Institute of Influenza, North-West Branch of the Russian Academy of Medical Sciences, St. Petersburg
Russian Federation
Russian Federation
References
1. http://www.who.int/csr/don/2009_11_13/en/index.html
2. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
3. Scholtissek C, Quack G., Klenk H. D., Webster R. G. How to overcome resistance of influenza A viruses against adamantane derivatives. Antiviral Res 1998; 37: 83-95.
4. Woodhead M., Lavanchy D., Johnston S. et al. Neuraminidase inhibitors: progress in the management of influenza. Int J Clin Pract 2000; 54: 9: 604-610.
5. Reed L. J., Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497.
6. Логинова С. Я., Борисевич С. В., Семенова И. А. и др. Изучение эффективности Ингавирина® in vitro в отношении возбудителя гриппа В. Антибиотики и химиотер 2009; 7-8: 13-15.
Review
For citations:
Zarubaev V.V., Garshinina A.V., Kalinina N.A., Shtro A.A., Nebolsin V.E., Kiselev O.I. Antiviral Activity of Ingavirin® in Experimental Lethal Influenza Due to Influenza Virus B in Albino Mice. Antibiot Khimioter = Antibiotics and Chemotherapy. 2010;55(3-4):8-11. (In Russ.)
Views:
3891
Email this article 